Showing results (231-240 of 270) with videos related to
Sort By:
Pageof 27
Cancer Letters|June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center StudyAmgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.Cancer Cell|May 13, 2020
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in CancerJian Carrot-Zhang, Nyasha Chambwe, Jeffrey S Damrauer, et al.Cancers|November 13, 2025
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible PatientsMorteza Salehjahromi, Hui Li, Eman Showkatian, et al.Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.JCO Precision Oncology|April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic ToxicityMitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-AnalysisLeonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.Pageof 27